DCGI Permits Biological E Ltd To Start Corbevax Vaccine Trial On Children

0
68

Corbevax: A Protein Subunit Vaccine

New Delhi: The Drugs Controller General of India (DCGI) has permitted the Hyderabad-based Indian biotechnology and biopharmaceutical company, Biological E Ltd to start the second phase of the COVID Vaccine trial on children in the age group of 5 to 18 years, subject to certain conditions, Sources.

Biologicals E Ltd’s Corbevax vaccine may be launched in India by the end of September. It is the first corona vaccine made from spike protein which will be available at the cheapest prices in the country. The central government has also made an advance payment of Rs 1500 crore for the supply of 30 crore doses of the vaccine.

LEAVE A REPLY

Please enter your comment!
Please enter your name here